New Alzheimer Association AUC, Patisiran Findings from AANEM, Evobrutinib findings from ECTRIMS
Neurology News Network for the week of October 20, 2018.
Thomas Leist, MD: Resetting the Immune System With Cladribine
The director of the Comprehensive Multiple Sclerosis Center at Thomas Jefferson University discussed the concept of lymphocyte depletion to reset the immune system.
Hideki Garren, MD, PhD: Measuring MS Progression With Floodlight Open
The smartphone application-led program, Floodlight Open, recently initiated in the US and Canada.
Richard Rudick, MD: The CogEval App in Clinical Practice
The goal of the free application is to make cognitive assessments routine in multiple sclerosis treatment.
Peter Calabresi, MD: Clinically Validating Neurofilament Light
One of the highly debated topics at ECTRIMS 2018 was the use of the investigational biomarker, neurofilament light, in the clinic.
When Disease Hijacks the Brain
Learn about the most insightful article Dr Lazzara has ever read in a research journal.
John Corboy, MD: The DISCO-MS Trial
The professor of neurology at Colorado University spoke about the ongoing phase IV trial to determine the safety of DMT discontinuation in MS.
Siponimod NDA Accepted, New Appropriate Use Criteria for Alzheimer Disease Diagnosis, Disease-Modifying Therapy
Neurology News Network for the week of Oct. 12, 2018.
Fernando Dangond, MD, MBA: Evobrutinib for Relapsing Multiple Sclerosis
The Head of Global Clinical Development in Neurology at EMD Serono provided insight into the therapy's performance in phase IIb.
Thomas Leist, MD: Immune Reconstitution Therapy for Multiple Sclerosis
The director of Thomas Jefferson's Comprehensive Multiple Sclerosis Center spoke about the introduction of this treatment method into MS.
Robert J. Fox, MD: Neurofilament Light as a Biomarker of Treatment Response
The staff neurologist at Cleveland Clinic’s Mellen Center for Multiple Sclerosis spoke about the current understanding of the biomarker.
Hideki Garren, MD, PhD: The ORATORIO-HAND Trial in PPMS
The Global Head of Neuroimmunology at Genentech discussed the upcoming phase III trial of ocrelizumab while on-site at ECTRIMS 2018.
Richard Rudick, MD: Using Data to Personalize MS Care
The vice president of Medical Research at Biogen spoke about the intersection between high-quality data utilization and individualized medicine in multiple sclerosis.
John Corboy, MD: Taking Patients Off Of Disease-Modifying Therapy
The professor of neurology at the University of Colorado posited that if certain criteria are met, it could be appropriate to take patients with multiple sclerosis off of DMT.
Eva Winnebeck, PhD: Temporal Dynamics of Sleep
The postdoctoral scientist spoke about an actimetry-based method studying the clinical relevance of temporal dynamics of sleep to make the dynamics easily quantifiable in everyday context.
Johan Verbraecken, MD, PhD: Challenges in Conducting Clinical Trials in OSA
The medical coordinator of the Multidisciplinary Sleep-Wake Disorders Center at Antwerp University Hospital spoke about how to address some of the issues faced in OSA treatment development.
Never Events Common in Parkinson, Donepezil Fails to Prevent Psychosis, Helping Patients Live Well
Neurology News Network for the week of October 6, 2018.
Tessa Blanken, MSc: Identification of Robust, Clinically Relevant Insomnia Subtypes
The identification of the subtypes allows future studies to target homogeneous subtype samples, resolve inconsistencies, personalize treatment and utilize preventive interventions.
Danny Eckert, PhD: Pharmacotherapies Reducing OSA Severity
Proof-of-concept studies using a targeted phenotypic approach to reduce obstructive sleep apnea severity are showing exciting results.
Danny Eckert, PhD: Unlocking New Targets For Pharmacological Therapy In OSA
The identification of 3 key non-anatomical contributors to OSA has unlocked new potential pharmacotherapies, a major advance for the field.
Stephen Silberstein, MD: Challenges in the Migraine Space
Silberstein spoke about the high prevalence of individuals with migraine in the United States, adding that the major problem in the space today is the lack of resources.
Jan Hedner, MD, PhD: Current Therapeutic Landscape of Obstructive Sleep Apnea
Recent research has identified novel potential pathophysiological mechanisms that could potentially serve to subclassify various phenotypes in obstructive sleep apnea.
Eva Winnebeck, PhD: Movement Rhythms During Sleep
The actimetry-based method allows for easily quantifiable sleep dynamics in real life context, enabling large-scale clinical studies to investigate the complex temporal dynamics of sleep.
Krista Lanctot, PhD: Managing Patients with Agitation
Lanctôt advised ruling out any possible underlying medical conditions that could be causing it, including pain, as well as starting with any non-pharmacologic interventions.
Geert Mayer, MD: Safety, Efficacy of Solriamfetol for Excessive Sleepiness In Narcolepsy, OSA
Long-term maintenance of efficacy was demonstrated with solriamfetol for treatment of excessive sleepiness with narcolepsy or obstructive sleep apnea.
Galcanezumab Approved, Pimavanserin Safety Confirmed, Treating Augmentation in RLS, Genetics in Alzheimer
Neurology News Network for the week of September 28, 2018.
A Study of Thousands: Adolescent Cognition and Alzheimer Disease
Potential risk factors may identify those at risk for AD and similar disorders as early as adolescence.
Irina Pikuleva, PhD: Activating CYP46A1 with Efavirenz
The Carl F. Asseff Professor of Ophthalmology and the Director of the Visual Sciences Research Center at Case Western Reserve University spoke about the beginnings of her work with efavirenz.
Geert Mayer, MD: Solriamfetol As Potential Therapy for Excessive Sleepiness in Narcolepsy, Obstructive Sleep Apnea
The neurologist and sleep specialist spoke about data from one of many studies investigating solriamfetol for treatment of narcolepsy and obstructive sleep apnea with remaining excessive daytime sleepiness.
Paul Newhouse, MD: Attacking Different Targets in Alzheimer
The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared his feelings on the early phase treatments.
